Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elisabetta Todisco, Ivana Lotesoriere, Federico Lussana, Valentina Mancini, Federica Gigli, Cristina Papayannidis, Michela Rondoni, Felicetto Ferrara, Sara Mastaglio, Annalina Piccioni, Michelina Dargenio, Andrea Corbingi, Francesco Mannelli, Alessandro Cignetti, Patrizia Zappasodi, Maria Paola Martelli, Monia Lunghi, Luana Fianchi, Patrizia Chiusolo, Francesco Grimaldi, Federica Pilo, Carla Fili, Debora Capelli, Massimo Breccia, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Luca Maurillo, Calogero Vetro, Alessandra Sperotto, Caterina Patti, Erika Borlenghi, Federica Lessi, Alessandro Isidori, Raffaele Palmieri, Caterina Alati, Samuele Gatani, Chiara Pessina, Paola Minetto, Carola Riva, Marco Frigeni, Nicola Stefano Fracchiolla, Carla Mazzone, Marco Cerrano, Massimo Bernardi, Michele Gottardi, Roberto Cairoli, Adriano Venditti, Livio Pagano, Roberto Lemoli, Fabio Guolo

Blood (2025) 146 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2025-4608

Published: 2025

Journal Articles

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Blood (2025) 146 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2025-3438

Published: 2025

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Blood (2025) 146 (Supplement 1): 3384.

https://doi.org/10.1182/blood-2025-3384

Published: 2025

Journal Articles

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study

Blood (2025) 146 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2025-3383

Published: 2025

Journal Articles

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

Blood (2025) 146 (Supplement 1): 6967.

https://doi.org/10.1182/blood-2025-6967

Published: 2025

Journal Articles

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

Livio Pagano, Alessandra Sperotto, Elisabetta Todisco, Roberto Lemoli, Massimo Breccia, Alessandro Rambaldi, Sara Galimberti, Saemi Park, Giovanna Dinelli, Rafaella Gentilella, Adriano Venditti

Blood (2025) 146 (Supplement 1): 5212.

https://doi.org/10.1182/blood-2025-5212

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

Arianna Savi, Giovanni Fornari, Johanna Umurungi, Beatrice Sani, Alessandro Cignetti, Ernesta Audisio, Elisabetta Todisco, Enrico Santinelli, Marianna Norata, Cristina Papayannidis, Raffaele Palmieri, Adriano Venditti, Monia Marchetti, Daniela Cilloni

Blood (2025) 146 (Supplement 1): 1624.

https://doi.org/10.1182/blood-2025-1624

Published: 2025

Journal Articles

Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study

Elisabetta Todisco, Martina Fontanini, Jr., Chiara Ronchini, Raffaella Furgi, Yinxiu Zhan, Viviana Amato, Alessandro Davini, Ramadan Safaa Mahmoud, Federica Gigli, Fabio Giglio, Gabriella Parma, Nicoletta Colombo, Samuele Gatani, Jr., Alessandro Rambaldi, Enrico Derenzini, Corrado Tarella, Pier Giuseppe Pelicci, Myriam Alcalay, Sr.

Blood (2024) 144 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2024-210236

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Blood (2024) 144 (Supplement 1): 835.

https://doi.org/10.1182/blood-2024-207892

Published: 2024

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Blood (2024) 144 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2024-210042

Published: 2024

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, Massimo Bernardi, Nicola Fracchiolla, Federica Gigli, Claudia Basilico, Lorenzo Masina, Erika Borlenghi, Alessandro Bruno, Giselda Gela, Diego Bertoli, Giuseppe Rossi, Alessandra Tucci, Federico Lussana, Elisabetta Todisco

Blood (2023) 142 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2023-181212

Published: 2023

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Blood (2023) 142 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2023-181142

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study

Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study

NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed AML: Evidence from the avalon cohort

VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort.

Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Applicability of SIE/Sies/GITMO Fitness Criteria to Therapy-Related and AML-MRC Receiving CPX-351: Results from a Large, Retrospective, Multicentric, Observational Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only